SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 4 — Focused Visit (Follow-up) — Friedrich Nietzsche — True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

PatientFriedrich Nietzsche
Date of birth1844-10-15
IdentifiersMRN HR-NI019-SYN-TD; SSN (made up) 000-19-5523
Document date1881-08-18
AuthorKonrad Ellison-Mbatha, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Four-week review after starting galcanezumab and the butalbital taper. [S]

History of Present Illness

Mr. Nietzsche returns four weeks after the consultation. He finished the taper eight days ago. In the first ten days of the taper his headaches were worse, with six days in a row of headache and vomiting on two, as he had been warned; since then they have eased. His diary shows 14 headache days in the past four weeks, 8 with migraine features, and only 2 headache days in the eight days since the last tablet. Apart from the scheduled taper doses he used acute medicine on 6 days: naproxen on 6, with metoclopramide on 3. He had no tremor, sweating, confusion or seizure; his sleep was worse for a few nights in the second week. The nurse phone check planned for the end of the first taper week did not take place. The first galcanezumab injection left a small red patch for a day. His constipation is no worse. The floaters in his right eye from two weeks ago are fading, with no new flashes. He has had contact lenses fitted and reads more comfortably with the left eye. He has had two CBT-I sessions and sleeps about five hours. [S]

ElementDetail
TaperCompleted eight days ago; rebound headache in the first ten days; no withdrawal symptoms
Headache days14 in the past four weeks, 8 with migraine features; 2 in the last eight days
Acute medicineNaproxen on 6 days, metoclopramide on 3, besides the taper doses
GalcanezumabMild redness at the first injection site; constipation unchanged
EyesContact lenses fitted; floaters fading
SleepAbout five hours; two CBT-I sessions

Review of Systems

SystemResultFinding
EyesPositiveFading floaters in the right eye; no new flashes or shadow
GastrointestinalPositiveVomiting on two days early in the taper; constipation no worse
NeurologicalPositiveHeadaches as in the diary; no tremor, confusion or seizure
PsychiatricNegativeMood steady; no hopelessness or thoughts of self-harm

4 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Butalbital 50 mg, acetaminophen 325 mg and caffeine 40 mg oral tablet, one or two tablets as needed for headache, taken on about 16 days a month, up to four tablets a day (prescribed abroad)One or two tablets as needed, about 16 days a month, up to four a dayOral route1880-11-03 to 1881-07-21stoppedS
Ibuprofen 200 mg oral tablet, two tablets as needed for headache on days without the combination tablets, about 4 days a month (over the counter)Two tablets as needed, about 4 days a monthOral route1880-11-03 to 1881-07-21stoppedS
Butalbital 50 mg, acetaminophen 325 mg and caffeine 40 mg oral tablet, scheduled taper: one tablet twice a day for 7 days, then one tablet a day for 7 days, then one tablet every other day for 7 days, then stopScheduled taper over three weeks: twice a day, then once a day, then every other day, then stop; not for extra dosesOral route1881-07-21 to 1881-08-10completedS
Naproxen 500 mg oral tablet, one tablet with food at the start of a migraine attack, may repeat once after 12 hours; no more than two days a weekOne tablet at attack onset, may repeat once after 12 hours; no more than two days a weekOral route1881-07-21activeS
Metoclopramide 10 mg oral tablet, one tablet with the acute medicine when a migraine attack brings nausea or vomiting; no more than two days a weekOne tablet with the acute medicine when nausea is present, no more than once a dayOral route1881-07-21activeS
Galcanezumab 120 mg/mL auto-injector, 240 mg (two injections) under the skin as a first loading dose, then 120 mg once a month, for chronic migraine preventionLoading dose of 240 mg (two injections) on the first day, then 120 mg every four weeksSubcutaneous route1881-07-21activeS
Sumatriptan 100 mg oral tablet, one tablet early in a migraine attack, may repeat once after 2 hours; no more than two days a week and no more than eight days a monthOne tablet at attack onset, may repeat once after 2 hours; up to 200 mg a day, no more than eight days a monthOral route1881-08-18activeS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
1881-08-18Body height174cmS
1881-08-18Body weight66.6kgS
1881-08-18Body mass index (BMI) [Ratio]22kg/m2S
1881-08-18Systolic blood pressure114mm[Hg]S
1881-08-18Diastolic blood pressure72mm[Hg]S
1881-08-18Heart rate64/minS
1881-08-18Respiratory rate14/minS
1881-08-18Body temperature36.6CelS
1881-08-18Oxygen saturation in Arterial blood by Pulse oximetry98%S

Physical Exam

Vital signs recorded on 1881-08-18; see the Vital Signs section. [S]

SystemFinding
GeneralWell; blood pressure 114/72, pulse 64
SkinFirst injection site on the abdomen healed
NeurologicalNo tremor; normal examination

Problems

ProblemClinical statusVerificationCodeProvenance
Frequent disabling headaches on about 20 days a month, with nausea, vomiting and light sensitivity, mostly right-sided, since childhood and more frequent over the past year, with a combination headache tablet containing butalbital taken on about 16 days a month; under evaluation with a headache diary, MRI, syphilis serology and a headache medicine consultationresolvedconfirmed R51.9S — Synthetic presenting problem anchored to his documented headaches; superseded when the consultation confirmed chronic migraine with medication overuse headache.
Chronic migraine without aura (15 or more headache days a month for more than three months, at least 8 with migraine features); ICHD-3 criteria met in a two-week diary; MRI of the brain normal; synthetic modern diagnosis linked to his documented headaches, which historians interpret differentlyactiveconfirmed G43.709S — Synthetic modern diagnosis made at the consultation; the historical diagnosis is disputed (CLM-0014), so this is not a claim about his real diagnosis.
Medication overuse headache from a butalbital, acetaminophen and caffeine combination on 10 or more days a month for more than three months, with ibuprofen on other days; resolved after a three-week taper and withdrawalactiveconfirmed G44.40S — Synthetic diagnosis made at the consultation, anchored to his documented use of many medicines and sedatives; not a claim about his real medicines.
High myopia in both eyes, much worse in the right eye, since early childhood, with long-standing poor vision in the right eye and unequal pupils; comprehensive eye examination bookedactiveconfirmed H52.13S — Synthetic modern coding of his documented severe myopia.
Pathologic (degenerative) myopia of the right eye with patchy chorioretinal atrophy of the macula, a posterior staphyloma and a tilted optic disc; no choroidal neovascularization on OCT; best corrected vision 20/100 in the right eyeactiveconfirmed H44.2E1S — Synthetic finding of the comprehensive eye examination, anchored to his documented poor right eye and the retrospective reading of it as myopic degeneration; not a claim about his real eyes.
Chronic insomnia, with difficulty falling asleep and early waking, worse on headache nights; no sleep medicine at intakeactiveconfirmed G47.00S — Synthetic sleep problem anchored to his documented severe insomnia; not a claim about his real sleep.
Acute posterior vitreous detachment of the right eye, with flashes and a floater, without a retinal break, detachment or vitreous hemorrhage on dilated examination, in an eye with pathologic myopiaactiveconfirmed H43.811S — Synthetic acute eye problem in a highly myopic eye; not a historical claim.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
ExaminationRed-flag screen (SNNOOP10): systemic signs, neurological signs, sudden onset, onset after 50, change in pattern, positional or Valsalva features, papilledema, progressive courseEvery visitCompleted todayNo red flags
SurveyHeadache diary: headache days, migraine days, attack features, triggersEvery visitCompleted today14 headache days in four weeks, 8 with migraine features, including the withdrawal weeks; 2 in the last eight days
Medication safetyAcute-medicine days (overuse limits: combination analgesics, triptans fewer than 10 days a month, simple analgesics fewer than 15)Every visitCompleted todayNaproxen on 6 days besides the scheduled taper doses; no butalbital since the taper ended
Medication safetyBarbiturate withdrawal: tremor, sweating, agitation, insomnia, confusion, seizures; rebound headacheDuring the three-week taper and at the first visit after itDeferredThe nurse phone check planned for the end of the first taper week did not take place. No harm resulted: he had rebound headache only, with no tremor, sweating, confusion or seizure, and he finished the taper as written. Corrective action: phone checks during any future taper are booked at the visit that starts it
Medication safetyGalcanezumab tolerability: injection sites, constipation, blood pressure, hypersensitivityBefore starting and at each injection visitCompleted todayMild redness at the first site for a day; constipation unchanged; blood pressure 114/72; second dose given today
Medication safetyCardiovascular screen before a triptanBefore the first triptan prescriptionCompleted todayNo chest pain, vascular disease, uncontrolled blood pressure or smoking; blood pressure 114/72
ExaminationPreventive efficacy (at least 50% fewer monthly migraine days; headache days below 15 a month)At three months on treatmentDueFour weeks on galcanezumab, including the withdrawal weeks; judged at about three months
SurveyDisability (MIDAS, recorded as its five items, and HIT-6)At baseline and after two to three months of treatmentDueRepeat at the eight-week review
SurveyMood (PHQ-9) and anxiety (GAD-7), with direct questions about hopelessness and self-harmAt baseline and at two to three months; questions at every visitDuePHQ-9 and GAD-7 at the eight-week review; no hopelessness or thoughts of self-harm today
ExaminationDilated re-examination after an acute posterior vitreous detachmentWithin six weeks of the detachment, sooner with new symptomsDueDetachment two weeks ago without a break; floaters fading; re-examination at the eight-week review
ExaminationContact lens fit and corrected visionAfter fittingCompleted todayLenses fitted; left eye 20/20 and right eye 20/100 with lenses
Self-managementSleep: hours, sleep diary, insomnia severity; no sedative sleeping tabletsEvery visitCompleted todayAbout five hours; two CBT-I sessions; no sleeping tablets

Goal progress:

Guideline basis: Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition (2018); The American Headache Society Consensus Statement: Update on integrating new migraine treatments into clinical practice (2021); Calcitonin gene-related peptide-targeting therapies are a first-line option for the prevention of migraine: An American Headache Society position statement update (2024); European Academy of Neurology guideline on the management of medication-overuse headache (2020); European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention - 2022 update (2022); Choosing wisely in headache medicine: the American Headache Society's list of five things physicians and patients should question (2013); Refractive Errors Preferred Practice Pattern (2023); Posterior Vitreous Detachment, Retinal Breaks, and Lattice Degeneration Preferred Practice Pattern (2025); Behavioral and psychological treatments for chronic insomnia disorder in adults: an American Academy of Sleep Medicine clinical practice guideline (2021); CMID: Clinical Monitoring Intelligence Database, depression, bipolar, and mood disorders monograph (2026)

Follow-up: Preventive visit in two weeks. Eight-week review in four weeks with the third galcanezumab injection and the repeat dilated eye examination. Same-day eye care for new flashes, a shower of floaters or a shadow. Next scheduled visit 1881-09-01: periodic adult preventive visit. [S]